Search Clinical Trials in the European Union

Duration
≤5 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
321-340 of 525 trials

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Low Ovarian Reserve: Factor-Rich Plasma Treatment

We are studying whether Factor-Rich Plasma injections can improve ovarian function and increase pregnancy rates in women with low ovarian reserve. This trial will also monitor any potential complications from the treatment.

Low Ovarian Reserve1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal Medicine

Cognitive Dysfunction in Schizophrenia: Clemastine and Exercise Study

We are investigating whether combining Clemastine with aerobic exercise can improve cognitive function in people with schizophrenia. The study aims to see if this approach enhances memory and overall functioning.

Schizophrenia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

New Treatment for Primary CNS Lymphoma: Optimizing MATRix

We are studying a modified treatment approach for patients with newly diagnosed primary CNS lymphoma to see if it improves survival and quality of life compared to standard therapy. This trial aims to find a safer and effective way to induce remission before further treatment.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Giant Cell Arteritis: Imaging Study with [18F]fluor-PEG-folate

We are investigating how well a special imaging technique shows changes in arteries of patients with giant cell arteritis before and after treatment. This may help us understand the disease better and improve future care.

Giant Cell Arteritis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Severe Vitamin D Deficiency: New Treatment Study

We are investigating a new treatment for people with severe vitamin D deficiency to see if it effectively raises vitamin D levels compared to another option. The study will also look at safety and patient satisfaction.

Severe Vitamin D Deficiency≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Thyroid Cancer Treatment: Radioiodine Strategies

We are comparing two treatment strategies for intermediate-risk differentiated thyroid cancer patients to see which is more effective. This study will also evaluate patient quality of life and side effects over time.

Thyroid Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

Skin Sarcoidosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Seminomas: EDEN Study on Reduced Therapy

We are testing a less intense treatment for patients with stage IIa/IIb seminomas under 3 cm to see if it helps prevent relapse. We’re also evaluating a biomarker to understand treatment response and its effects on quality of life.

Stage IIa/IIb Seminoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Plaque Psoriasis: Bimekizumab vs. Topical Corticosteroids

We are studying whether bimekizumab can better control plaque psoriasis compared to standard topical treatments. This trial aims to improve disease management and quality of life for patients.

Eruptive Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Vaborem® for Serious Infections in Children

We are studying how Vaborem® is processed in the body and its safety in children with suspected or confirmed Gram-negative infections. This trial includes kids from birth to under 18 years old.

Acute Pyelonephritis≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Atrial Fibrillation: IV Flecainide with Ranolazine

We are comparing the effectiveness of a combination of IV flecainide and oral ranolazine against IV flecainide alone for patients with recent onset atrial fibrillation. This study aims to find out which treatment better restores normal heart rhythm.

Atrial Fibrillation (AF)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiology

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Irritable Bowel Syndrome: GSL-01-001 Treatment

We are testing a new oral medication for people with Irritable Bowel Syndrome to see if it helps control symptoms like pain and bloating. The study also aims to evaluate its safety and impact on quality of life.

Irritable Bowel Syndrome (IBS)6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Leukemia: Venetoclax with Stem Cell Transplant

We are evaluating the safety and effectiveness of Venetoclax combined with standard treatment for patients with high-risk MDS, CMML, or sAML undergoing stem cell transplantation. This study aims to improve outcomes and reduce complications during treatment.

Leukemia>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Psoriasis: [18F]Fluoride PET-CT Imaging Study

We are investigating if [18F]Fluoride PET-CT scans can detect early bone changes in psoriasis patients at risk for psoriatic arthritis. This study aims to see if this imaging method is effective for early detection.

Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyRheumatology

Colorectal Cancer Prevention: Mesalamine for Lynch Syndrome

We are studying whether mesalamine can help prevent colorectal cancer in patients with Lynch syndrome. This trial compares mesalamine to a placebo to see if it reduces the occurrence of tumors.

Lynch Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyOncology

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology